Logo image of INMB

INMUNE BIO INC (INMB) Stock Fundamental Analysis

NASDAQ:INMB - Nasdaq - US45782T1051 - Common Stock - Currency: USD

7.76  -0.09 (-1.15%)

Fundamental Rating

3

Taking everything into account, INMB scores 3 out of 10 in our fundamental rating. INMB was compared to 566 industry peers in the Biotechnology industry. While INMB has a great health rating, there are worries on its profitability. INMB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INMB has reported negative net income.
INMB had a negative operating cash flow in the past year.
INMB had negative earnings in each of the past 5 years.
In the past 5 years INMB always reported negative operating cash flow.
INMB Yearly Net Income VS EBIT VS OCF VS FCFINMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of INMB (-106.37%) is worse than 78.45% of its industry peers.
INMB has a worse Return On Equity (-131.11%) than 60.95% of its industry peers.
Industry RankSector Rank
ROA -106.37%
ROE -131.11%
ROIC N/A
ROA(3y)-64.13%
ROA(5y)-50.5%
ROE(3y)-85.07%
ROE(5y)-64.85%
ROIC(3y)N/A
ROIC(5y)N/A
INMB Yearly ROA, ROE, ROICINMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INMB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INMB Yearly Profit, Operating, Gross MarginsINMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K

More info and screens

7

2. Health

2.1 Basic Checks

INMB has more shares outstanding than it did 1 year ago.
INMB has more shares outstanding than it did 5 years ago.
There is no outstanding debt for INMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INMB Yearly Shares OutstandingINMB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
INMB Yearly Total Debt VS Total AssetsINMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

INMB has an Altman-Z score of 5.64. This indicates that INMB is financially healthy and has little risk of bankruptcy at the moment.
INMB's Altman-Z score of 5.64 is amongst the best of the industry. INMB outperforms 81.45% of its industry peers.
There is no outstanding debt for INMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.64
ROIC/WACCN/A
WACCN/A
INMB Yearly LT Debt VS Equity VS FCFINMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

INMB has a Current Ratio of 3.14. This indicates that INMB is financially healthy and has no problem in meeting its short term obligations.
INMB's Current ratio of 3.14 is on the low side compared to the rest of the industry. INMB is outperformed by 63.43% of its industry peers.
A Quick Ratio of 3.14 indicates that INMB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.14, INMB is doing worse than 60.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 3.14
INMB Yearly Current Assets VS Current LiabilitesINMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for INMB have decreased strongly by -26.35% in the last year.
Looking at the last year, INMB shows a very negative growth in Revenue. The Revenue has decreased by -91.14% in the last year.
The Revenue for INMB have been decreasing by -57.31% on average. This is quite bad
EPS 1Y (TTM)-26.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.89%
Revenue 1Y (TTM)-91.14%
Revenue growth 3Y-57.31%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 18.83% on average over the next years. This is quite good.
INMB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 572.34% yearly.
EPS Next Y13.08%
EPS Next 2Y8.49%
EPS Next 3Y11.15%
EPS Next 5Y18.83%
Revenue Next Year-100%
Revenue Next 2Y2169.84%
Revenue Next 3Y1041.86%
Revenue Next 5Y572.34%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INMB Yearly Revenue VS EstimatesINMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
INMB Yearly EPS VS EstimatesINMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year INMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INMB Price Earnings VS Forward Price EarningsINMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INMB Per share dataINMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.49%
EPS Next 3Y11.15%

More info and screens

0

5. Dividend

5.1 Amount

INMB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INMUNE BIO INC

NASDAQ:INMB (4/30/2025, 10:43:19 AM)

7.76

-0.09 (-1.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)04-30 2025-04-30
Inst Owners27.99%
Inst Owner Change0.39%
Ins Owners20.37%
Ins Owner Change0%
Market Cap178.32M
Analysts83.64
Price Target23.87 (207.6%)
Short Float %36.14%
Short Ratio22.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.47%
Min EPS beat(2)-18.44%
Max EPS beat(2)27.38%
EPS beat(4)2
Avg EPS beat(4)4.84%
Min EPS beat(4)-18.44%
Max EPS beat(4)27.38%
EPS beat(8)3
Avg EPS beat(8)-207.27%
EPS beat(12)7
Avg EPS beat(12)-128.06%
EPS beat(16)8
Avg EPS beat(16)-101.48%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)17.98%
EPS NQ rev (1m)5.62%
EPS NQ rev (3m)0%
EPS NY rev (1m)6.35%
EPS NY rev (3m)11.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12737.49
P/FCF N/A
P/OCF N/A
P/B 5.56
P/tB 11.44
EV/EBITDA N/A
EPS(TTM)-2.11
EYN/A
EPS(NY)-1.83
Fwd EYN/A
FCF(TTM)-1.45
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS0
BVpS1.4
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -106.37%
ROE -131.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.13%
ROA(5y)-50.5%
ROE(3y)-85.07%
ROE(5y)-64.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.14
Quick Ratio 3.14
Altman-Z 5.64
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.89%
EPS Next Y13.08%
EPS Next 2Y8.49%
EPS Next 3Y11.15%
EPS Next 5Y18.83%
Revenue 1Y (TTM)-91.14%
Revenue growth 3Y-57.31%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y2169.84%
Revenue Next 3Y1041.86%
Revenue Next 5Y572.34%
EBIT growth 1Y-43.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-178.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-178.47%
OCF growth 3YN/A
OCF growth 5YN/A